Status:
COMPLETED
Alvopem® (Pemetrexed) Safety Assessment
Lead Sponsor:
NanoAlvand
Conditions:
Non Small Cell Lung Cancer
Malignant Pleural Mesothelioma
Eligibility:
All Genders
Brief Summary
The present study was a phase IV, post-marketing, observational study for safety evaluation of Alvopem® use in Iranian patients with non-small cell lung cancer and malignant pleural mesothelioma. No c...
Detailed Description
The present study was a phase IV, post-marketing, observational study for safety evaluation of Alvopem® use in Iranian patients with non-small cell lung cancer and malignant pleural mesothelioma. Dat...
Eligibility Criteria
Inclusion
- Patients diagnosed with non-small cell lung cancer and malignant pleural mesothelioma under chemotherapy regimens with Alvopem® were enrolled in the study.
Exclusion
- There were no exclusion criteria for this study.
Key Trial Info
Start Date :
March 15 2016
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
January 22 2020
Estimated Enrollment :
199 Patients enrolled
Trial Details
Trial ID
NCT04843007
Start Date
March 15 2016
End Date
January 22 2020
Last Update
October 23 2024
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.